JBSS 38.16 John B. Sanfilippo & Son $JBSS Hit a 52 week

New Post Public Reply Private Reply Replies (0) Message Board

Nov 17, 2014 at 11:16 AM

JBSS 38.16 John B. Sanfilippo & Son $JBSS Hit a 52 week high of 38.91 Closing the day 09:43 at 38.16 +0.25 +0.66% With a day low of 38.07 and a total volume of 4,735.

JBSS Recent Posts: http://investorshangout.com/John-B-Sanfilippo...BSS-54529/

JBSS John B. Sanfilippo & Son Recent Headline News

John B. Sanfilippo & Son, Inc. to Present at the Southwest IDEAS Investor Conference on November 19th & 20th in Dallas
Business Wire - Thu Nov 13, 4:13PM CST
John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS), today announced that Mike Valentine, Chief Financial Officer and Frank Pellegrino, Sr. Vice President of Finance will present at the Southwest IDEAS Investor Conference on Thursday, November 20, 2014 at the Marriott - Quorum Hotel in Addison, Texas. John B. Sanfilippo & Son, Inc.'s presentation is scheduled to begin at 1:50 p.m. Central. The presentation will be webcast live and may be accessed at the conference website, www.IDEASConferences.com, or in the investor relations section of the company's website: http://www.jbssinc.com.
JBSS: 38.21 (+0.30)

John B. Sanfilippo & Son declares $1.50 dividend
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 4:47PM CDT

JBSS: 38.21 (+0.30)

John B. Sanfilippo & Son, Inc. Board Declares Special Cash Dividend of $1.50 per share of Common Stock and $1.50 per share of Class A Common Stock
Business Wire - Tue Oct 28, 4:04PM CDT
John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS) (the "Company"

today announced that its Board of Directors (the "Board"

declared a special cash dividend (the "Dividend"

of $1.50 per share on all issued and outstanding shares of Common Stock of the Company and $1.50 per share on all issued and outstanding shares of Class A Common Stock of the Company.
JBSS: 38.21 (+0.30)

John B. Sanfilippo & Son Is A Strong Buy For Long Term Investors
Jaxon Research - at Seeking Alpha - Tue Oct 28, 10:24AM CDT

JBSS: 38.21 (+0.30)

Update: John B. Sanfilippo & Son's Weak Fiscal Q1'15
Marshall Hargrave - at Seeking Alpha - Tue Oct 28, 1:55AM CDT

JBSS: 38.21 (+0.30)

John B Sanfilippo & Son's (JBSS) CEO Jeffrey Sanfilippo on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Oct 24, 1:50PM CDT

JBSS: 38.21 (+0.30)

John B. Sanfilippo & Son EPS of $0.53
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 3:27PM CDT

JBSS: 38.21 (+0.30)

John B. Sanfilippo & Son, Inc. Net Sales Increased by 16% on Higher Pricing and Strong Sales Volume
Business Wire - Thu Oct 23, 3:10PM CDT
--Net sales increased by 16.0%
JBSS: 38.21 (+0.30)

Shares of JBSS Up 43.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Oct 20, 9:09AM CDT
SmarTrend identified an Uptrend for John B. Sanfilippo & Son (NASDAQ:JBSS) on May 1st, 2014 at $24.38. In approximately 6 months, John B. Sanfilippo & Son has returned 43.68% as of today's recent price of $35.03.
JBSS: 38.21 (+0.30)

John B. Sanfilippo & Son, Inc. 1st Quarter Fiscal 2015 Operating Results Conference Call
GlobeNewswire - Fri Oct 17, 4:00PM CDT
John B. Sanfilippo & Son, Inc. (Nasdaq:JBSS), a major processor and distributor of snack and recipe nut products, will hold its quarterly conference call to discuss first quarter fiscal 2015 operating results on Friday, October 24, 2014 at 10:00 a.m. Eastern Time (9:00 a.m. Central Time). First quarter fiscal 2015 results are expected to be released after the market closes on Thursday, October 23, 2014.
JBSS: 38.21 (+0.30)

Today In SA PRO: Tuesday, October 14
SA PRO Top Ideas - at Seeking Alpha - Wed Oct 15, 4:00AM CDT
Outstanding Performance Award Winner #1: Top Short Idea on MCHX (Marchex, Inc.) by Ariana Research, published July 11, 2014. Return to date: +68% (See author update » ) Outstanding Performance Award Winner #2: PRO Short Idea on ITT...
WATT: 8.89 (-0.09), JBSS: 38.21 (+0.30)

John B. Sanfilippo & Son Has Returned 34.3% Since SmarTrend Recommendation (JBSS)
Comtex SmarTrend(R) - Fri Oct 10, 5:11PM CDT
SmarTrend identified an Uptrend for John B. Sanfilippo & Son (NASDAQ:JBSS) on May 1st, 2014 at $24.38. In approximately 5 months, John B. Sanfilippo & Son has returned 34.33% as of today's recent price of $32.75.
JBSS: 38.21 (+0.30)

John B. Sanfilippo & Son Up 32.9% Since SmarTrend Uptrend Call (JBSS)
Comtex SmarTrend(R) - Fri Oct 03, 4:45PM CDT
SmarTrend identified an Uptrend for John B. Sanfilippo & Son (NASDAQ:JBSS) on May 1st, 2014 at $24.38. In approximately 5 months, John B. Sanfilippo & Son has returned 32.90% as of today's recent price of $32.40.
JBSS: 38.21 (+0.30)

Fisher Announces Statewide Campaign and $40,000 Donation to Feeding Texas
PR Newswire - Fri Oct 03, 9:00AM CDT
Fisher® Nuts announced a statewide campaign to bring Texas communities together to help feed hungry families this holiday season. In its third year partnering with Feeding Texas (formerly the Texas Food Bank Network) for the Fisher Shares & Cares campaign, Fisher is donating $40,000 that will be used to help feed 400,000 Texans throughout the season.
JBSS: 38.21 (+0.30)

33.6% Return Seen to Date on SmarTrend John B. Sanfilippo & Son Call (JBSS)
Comtex SmarTrend(R) - Fri Sep 26, 10:58AM CDT
SmarTrend identified an Uptrend for John B. Sanfilippo & Son (NASDAQ:JBSS) on May 1st, 2014 at $24.38. In approximately 5 months, John B. Sanfilippo & Son has returned 33.55% as of today's recent price of $32.56.
JBSS: 38.21 (+0.30)

Shares of JBSS Up 32.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Sep 19, 9:36AM CDT
SmarTrend identified an Uptrend for John B. Sanfilippo & Son (NASDAQ:JBSS) on May 1st, 2014 at $24.38. In approximately 5 months, John B. Sanfilippo & Son has returned 32.32% as of today's recent price of $32.26.
JBSS: 38.21 (+0.30)

Uptrend Call Working As John B. Sanfilippo & Son Stock Rises 33.0% (JBSS)
Comtex SmarTrend(R) - Fri Sep 12, 9:10AM CDT
SmarTrend identified an Uptrend for John B. Sanfilippo & Son (NASDAQ:JBSS) on May 1st, 2014 at $24.38. In approximately 4 months, John B. Sanfilippo & Son has returned 32.98% as of today's recent price of $32.42.
JBSS: 38.21 (+0.30)

Fisher Nuts and Chef Alex Guarnaschelli Announce Second Annual "My Fresh Twist" Recipe Contest
PR Newswire - Tue Sep 09, 10:45AM CDT
Fisher® Nuts has announced the second annual "My Fresh Twist" recipe contest today. Beginning now through October 21, 2014 consumers are invited to submit an original recipe using walnuts, almonds or pecans to www.myfreshtwist.com for a chance to win a grand prize that includes a trip for two to New York City to meet Chef Alex Guarnaschelli.
JBSS: 38.21 (+0.30)

John B. Sanfilippo & Son Has Returned 27.8% Since SmarTrend Recommendation (JBSS)
Comtex SmarTrend(R) - Thu Aug 28, 10:58AM CDT
SmarTrend identified an Uptrend for John B. Sanfilippo & Son (NASDAQ:JBSS) on May 1st, 2014 at $24.38. In approximately 4 months, John B. Sanfilippo & Son has returned 27.75% as of today's recent price of $31.15.
JBSS: 38.21 (+0.30)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...